Health Boards
Wed-25-11-2015, 21:58 PM
(Wed-25-11-2015, 21:45 PM)jiml Wrote:(Wed-25-11-2015, 21:32 PM)Fred Wrote: They haven't said yet Jim as far as I know but to quote the reason for a no for psoriatic arthritis I would say the reason is much the same.
Quote:
compared with TNF-alpha inhibitors, apremilast was the least clinically effective for treating psoriatic arthritis although some costs were saved by its use. Importantly, there was not enough robust evidence demonstrating that apremilast slows progression of the disease compared to TNF-alpha inhibitors.
Again I'll say what I said before there's no way to get robust evidence without having it out there being used ,
True but they have to weigh up the costs to the NHS against the effectiveness of the treatment by what evidence they have. As you know there are a lot of treatments in the pipeline and what I have read on Otezla so far it's not looking good, so they are better off spending their money on something like your oral treatment Fumaderm which already has a good track record.
